Abstract 15104: Drug-Eluting Stents for the Treatment of Left Main Coronary Artery Disease with Bifurcated Lesions: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent: Multicenter Registry in Asia
Aim: The aim of this study is to compare the safety, efficacy and durability of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with left main coronary arteries (LMT) stenosis.
Methods: A prospective analysis of 1127 LMT stenosis (321 SES, 277 PES, 129 ZES-R, 172 BES, 55 ECS, 173 EES) in six high volume Asian centers after successful stenting in LMT stenosis was performed. The study endpoints were 30 days major adverse cardiac events (MACE) and 12, 24, 36 and 48 months target lesion revascularization (TLR) and MACE in those 6 groups.
Results: See table for clinical results.
Conclusion: The use of drug-eluting stents in patients with LMT stenosis was safe with low acute complication. Patients treated with BES and EES showed lesser rate of restenosis compared with ZES-R and ECS.
- © 2012 by American Heart Association, Inc.